Sjögren’s Syndrome News

Heart rate monitoring may be a crucial means of detecting rhythm abnormalities in the fetuses of pregnant individuals who are positive for anti-Ro/SSA antibodies, according to data presented at ACR Convergence 2021.

Healio announced the launch of Rheum and Boards, a quiz-based, online learning resource for rheumatologists, according to a Healio press release.

It is likely that one or more “promising treatments” currently being investigated for Sjögren’s syndrome will come into use within the next 3 to 5 years, according to a presenter at the 2021 Congress of Clinical Rheumatology-West.

Although immunosuppressives remain the cornerstone for managing underlying interstitial lung disease in connective tissue diseases, new drug approvals could help shift the treatment paradigm, according to data presented here.

Cancer screening recommendations for patients with autoimmune diseases largely rely on clinical experience and extrapolation in the absence of abundant data, according to a speaker at the 2021 Congress of Clinical Rheumatology-East meeting.

While the 2021 consensus guidelines for pulmonary disease in Sjögren’s syndrome may have shed light on this underdiagnosed complication, gaps remain in identification and management of the disease, noted a presenter here.

Novel therapeutic approaches and a robust drug pipeline may provide hope for patients with Sjögren’s syndrome, according to a presenter at the 2021 Congress of Clinical Rheumatology-East.

Approximately 27% of patients with a rheumatic disease experienced a change in employment status during the early months of the COVID-19 pandemic, according to survey results published in The Lancet Rheumatology.

This past spring, two studies shed light on how some of the largest clinician organizations and publishers in rheumatology, including the American College of Rheumatology and EULAR, have failed to provide adequate training materials or clear guidelines when it comes to caring for patients of color.

Although the seroprevalence of SARS-CoV-2 in patients with immune-mediated inflammatory diseases is comparable to the general population, increased systemic inflammation among these patients is linked to symptomatic COVID-19, according to researchers.